Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol,levonorgestrel -

Málta - angol - Medicines Authority

pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - gestodene, ethinylestradiol - film-coated tablet - gestodene ethinylestradiol - sex hormones and modulators of the genital system

Málta - angol - Medicines Authority

gedeon richter plc gyomroi ut 19-21 1103 budapest, hungary - gestodene, ethinylestradiol - transdermal patch - gestodene 2.1 mg ethinylestradiol 0.55 mg - sex hormones and modulators of the genital system

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ethinylestradiol, quantity: 0.03 mg; gestodene, quantity: 0.075 mg - tablet, sugar coated - excipient ingredients: brilliant scarlet 4r; magnesium stearate; macrogol 6000; calcium carbonate; lactose monohydrate; erythrosine; purified talc; maize starch; sucrose; glycol montanate; povidone - for the prevention of pregnancy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yaz is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yaz for pmdd was not assessed beyond 3 cycles. yaz has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; lactose monohydrate; magnesium stearate; hypromellose; microcrystalline cellulose - indications: petibelle is indicated for use as an oral contraceptive.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; purified talc; titanium dioxide; magnesium stearate; hypromellose; microcrystalline cellulose - indications: yasmin is indicated for use as an oral contraceptive.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 30 microgram; drospirenone, quantity: 3 mg - tablet - excipient ingredients: maize starch; magnesium stearate; pregelatinised maize starch; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - for use as an oral contraceptive

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 400 - bella is indicated for use:,? as an oral contraceptive.,? for the treatment of moderate acne vulgaris in women who seek oral contraception.,? for the treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of ethinylestradiol/drospirenone 20 microgram/3 mg tablets for pmdd was not assessed beyond 3 cycles. ethinylestradiol/drospirenone 20 microgram/3 mg tablets have not been evaluated for treatment of pms (premenstrual syndrome) (see section 5.1 pharmacodynamic properties ? clinical trials).

Belgium - angol - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - ethinylestradiol 0,03 mg; gestodene 0,075 mg - coated tablet - 0,075 mg - 0,03 mg - ethinylestradiol 30 µg; gestodene 75 µg - gestodene and ethinylestradiol